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ABSTRACT
Background
To ensure the safety and effectiveness of cancer man-
agement, it is important for physicians treating cancer
patients to know whether their patients are using
complementary and alternative medicine (CAM) and if
so, why.
Objective
Here, we discuss the ethical and legal obligations of
physicians to discuss CAM use in an oncology setting,
and we provide practical advice on how patient–pro-
vider communication about CAM can be improved.
Results
Physicians have both ethical and legal obligations to
their patients, including the obligation to respect pa-
tient autonomy. This latter obligation extends to use of
CAM by patients and needs to be addressed beginning
early in the patient–provider relationship. Because lack
of education in this field and lack of time during pa-
tient consultations are barriers to talking with patients
about CAM, we provide resources to facilitate such dis-
cussions. These resources include suggestions on how
to discuss the topic of CAM and a wide range of infor-
mation sources.
Conclusions
Discussing CAM with patients is the physician’s respon-
sibility, and such discussion will facilitate evidence-
based, patient-centred cancer care.
KEY WORDS
Complementary and alternative medicine, CAM, phy-
sicians, patients, communication
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1. INTRODUCTION
Studies report that most patients undergoing cancer
treatment also choose to use selected forms of comple-
mentary and alternative medicine (CAM), including
natural health products 1,2. Reasons cited by cancer
patients for CAM use include treating the cancer, man-
aging treatment side effects, enhancing quality of life
and well-being, boosting the immune system, main-
taining hope, and having more control over their can-
cer care 2–4.
It is important that physicians treating cancer pa-
tients know whether their patients are using CAM and,
if so, why. First, physicians need to know because of
the possibility of direct adverse events associated with
the use of CAM. Second, interaction effects between
conventional medicine and CAM are possible, and the
harms and benefits of CAM may be misattributed to
conventional treatment and thus may complicate treat-
ment regimens. Third, patients may delay the use of
conventional treatment when using CAM. Finally, know-
ing why patients are using CAM may provide important
information about beliefs, values, expectations, and
hopes on the part of the patient and will facilitate build-
ing a trusting relationship that will enhance the deliv-
ery of patient-centred cancer care.
However, research has shown that 40%–77% of
patients who use CAM therapies do not disclose their
use of or interest in CAM, or their desire to use CAM, to
their physicians because of concerns that the physi-
cians will react negatively or will dismiss their ques-
tions 5–7. Patients may also think that physicians do not
need to know that they are using CAM, because the
patients may believe that CAM therapies are natural,
completely safe, and not within the physicians’ scope
of practice. Finally, patients often do not tell, simply
because physicians do not ask about CAM use.
In this paper, we discuss the ethical and legal
obligations of physicians to discuss CAM use in an
oncology setting, and we provide practical advice on
how patient–provider communication about CAM can
be improved.VERHOEF et al.
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2. DISCUSSION
2.1 Obligation of Physicians to Discuss CAM
Physicians have both ethical and legal obligations to
their patients, including the obligation to respect pa-
tient autonomy. Operationally, respecting patient au-
tonomy in the context of treatment decision-making
means allowing patients to make choices 8. However,
choice is meaningless if it is not made in light of all
relevant information and advice 9. Although patients
are the ones who must make the treatment decisions,
physicians have the duty to inform patients about all
therapeutic options, including CAM. This means that
physicians must be prepared to provide information and
advice about
• benefits and likely outcomes of treatment,
• risks involved in treatment,
• possibility and probability of complications, and
• side effects and alternative treatment options.
This information is needed to meet the traditional
ethical principles of non-maleficence (do no harm)
and beneficence (offer a benefit) 10. Specifically for
CAM, the obligation to provide information and ad-
vice means that where risks are unknown and ben-
efits are uncertain, it is necessary to highlight this
absence of information.
Canadian courts have been very liberal and expan-
sive in interpreting the disclosure obligations of physi-
cians. In the context of informed consent, physicians
are legally and ethically required to provide patients
with detailed information about the evidence (for and
against) the possible efficacy of treatments and to dis-
cuss costs, risks, and how a given treatment compares
with other therapeutic options 11,12. The informed con-
sent approach applies whether the recommended treat-
ment is labelled biomedical or CAM, and it raises the
question of whether physicians must discuss CAM treat-
ment options to fulfil the informed consent requirement
to compare a given treatment option with other thera-
peutic options.
It has been argued that an exploration of CAM treat-
ment options with patients is necessary, especially
when information about CAM options will be material—
that is, significant—to a decision about a conventional
treatment. Thus, if a patient’s decision about pursuing
a particular biomedical treatment is likely to be influ-
enced by knowing about specific CAM treatments (in-
cluding evidence of their safety, efficacy, and cost),
then a physician has an obligation to include a discus-
sion of these CAM options as part of the informed con-
sent process 12,13. Given the widespread use of CAM
among Canadians diagnosed with cancer, it appears
reasonable to assume that CAM options will be mate-
rial to many patients. In addition, perhaps the only way
to determine if CAM options are relevant factors in the
decision-making processes of patients is to open a dia-
logue about the issues.
There is increasing consensus in the literature about
the importance of fully disclosing detailed information
about the risks and benefits of CAM interventions, in-
cluding clear explanations of what is not known about
them 11–13. The focus appears to be on protecting pa-
tients from physicians that promote CAM products and
therapies beyond what is believed by others to be sup-
ported by scientific evidence. Legally, physicians are
required to practice in accordance with the “standard
of care,” which generally refers to “the level of care
the average and prudent health care professional in a
given community would provide” 13. This standard
changes over time and across cultural contexts. Al-
though therapies with scientific evidence of safety and
efficacy are unlikely to be judged outside the standard
of care, scientific evidence is not the only criterion
upon which such judgments are made.
In today’s culture of evidence-based practice, sci-
entific evidence is becoming increasingly important 11,
but clinical judgment and patient values are important,
too 14. Thus, physicians who provide or recommend
CAM therapies for which there is little evidence could
leave themselves open to charges of medical malprac-
tice 11,13. In contrast, requirements to fully discuss CAM
options as “alternative” treatment options when rec-
ommending a conventional biomedical treatment may
soon become standard practice.
Adams et al. 15 identified a wide range of patient-
and physician-related factors that affect decision-
making and subsequent use of CAM, including
• severity of the illness,
• curability with conventional treatment,
• side effects of conventional treatment,
• quality of evidence of safety and efficacy of CAM,
• degree of understanding of risks and benefits,
• knowing and voluntary acceptance of risks by the
patient, and
• commitment to CAM use by the patient.
Clearly, the need for physicians to assist patients
in treatment decision-making is high and requires more
than being informed about CAM. Physicians also need
to have effective (and non-judgmental) communica-
tion skills to manage the discussion. Patient–physician
communication plays a crucial role, because these is-
sues are best resolved by means of shared decision-
making between patient and physician, where sufficient
information is exchanged to create a consensus ap-
proach to deciding on the optimal clinical course.
2.2 How to Discuss CAM with Patients
It is becoming increasingly clear that patients have many
legitimate needs and concerns that are not being met by
conventional medicine. By adhering to the ethical crite-
ria for informed decision-making and by honouring pa-
tient autonomy, physicians should be able to engage inTALKING TO CANCER PATIENTS ABOUT CAM
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open discussions with their patients about CAM and to
enable their patients to make sound decisions 6.
Not communicating with patients about CAM may
not only result in decreased trust within the therapeutic
relationship, but also in selection by the patients of
harmful, ineffective, and costly CAM therapies. Patients
who use CAM may have unidentified needs or may be
dissatisfied with the conventional care they are receiv-
ing. Once the issue of CAM use is raised, the unidenti-
fied needs or dissatisfaction may come to the forefront
and be addressed. However, the fact that relatively few
physicians talk with their patients about CAM suggests
that these conversations are not easy for physicians.
Lack of training in CAM, limited training in communi-
cation skills, limited knowledge about CAM, lack of
scientific evidence about the risks and benefits of CAM,
and skepticism towards CAM all appear to prevent phy-
sician engagement in such discussions.
Tasaki 16 found that patients identified these major
barriers to successful discussions of CAM:
• perceived indifference or opposition towards CAM
by the physician,
• emphasis on scientific evidence by the physician,
and
• anticipation on the part of the patient of a negative
response from the physician.
Initiating communication about CAM is crucial.
Table I summarizes a number of suggestions on how
to encourage patients to talk about CAM. Foley 19
underscores the need for such conversations by talking
about “the need for us as oncology professionals to
‘Seek first to understand,’ to be open and to learn from
our patients to serve them better.”
Eisenberg 20 was one of the first to propose a step-
by-step strategy that conventionally trained physicians
could use to proactively discuss CAM use. This strat-
egy involves a formal discussion of the treatment pref-
erences and expectations of patients, the maintenance
of symptom diaries, and follow-up visits to monitor for
potentially harmful situations. In the absence of medi-
cal and legal guidelines, the proposed management plan
emphasizes patient safety, the need for documentation
in patient records, and the importance of shared deci-
sion-making. Although this strategy may be impracti-
cal and cumbersome in practice, Eisenberg should be
credited for highlighting essential elements in physi-
cian–patient communication and for focusing on
documentation and follow-up.
Informally, the five major steps to intervention—
“ask, advise, assess, assist, and arrange” (5 A’s) 21—
have been mentioned as important guidelines for
communicating about CAM, but a more focused approach
has been presented by Cohen et al. 13. They suggest
exploration (of the patient’s main issues), validation (ac-
knowledge and commend the patient for seeking to re-
solve symptoms and improve health), empathy (with
the patient’s desire to do everything possible), evalua-
tion (consult with colleagues and other experts, and con-
sult reputable sources of information), communication
(share findings with the patient), and documentation of
TABLE I  Communicating with patients: keeping the door open 17,18
What follows is a list of possible questions and issues that physicians can raise. Obviously, it is neither possible nor necessary to address all
areas; however, even one good question may be the key to either opening the door to discussing CAM or keeping the door open.
1. Always ask about complementary and alternative medicine (CAM) use—for example, “What else are you doing to take care of your
cancer?” Ask in an open, non-judgmental way, and avoid using labels such as quackery, unscientific, and so on.
2. Watch for “non disclosing” clues: “You have read a lot about this. Have you seen other types of practitioners?”
3. Give permission for the patient to raise the topic by asking, “Many of my patients are interested in trying complementary thera-
pies.  Have you used any other therapies for this problem?”
4. Check with patients about their explanatory models: “What do you think is causing your symptoms [or cancer (because many
patients have strong opinions of causes of cancer)]?”
5. Seek more information from patients and other sources: “Do you have any articles you can share with me?”
a. Be prepared for patients doing their own research.
b. Be aware of what they are being told about CAM.
6. Explore why patients are using CAM, and learn about their beliefs and values. It is important to consider that
a. a great deal more than evidence goes into a patient’s decision to use CAM.
b. for many patients, care (enhancing well-being, easing suffering) is as important as cure.
7. Discuss the patient’s treatment preferences and expectations.
8. Review issues of efficiency and safety with respect to CAM.
9. Be frank about your level of understanding or knowledge. It is okay not to know everything about CAM.
10. Support the patient in efforts to obtain answers to important questions about risk and benefit. Ask yourself:
a. Is the CAM therapy really dangerous?
b. Does it prohibit necessary medical care?
c. Can you work within the patient’s belief system to provide good care?
    If the answer to the last question is yes, the next steps include negotiation and education. If the answer is no, the next step
    would be to arrive at a mutually acceptable course of action.
11. Discussing CAM use does not mean that you are endorsing or promoting CAM use.VERHOEF et al.
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the conversations with the patient and of the patient’s
progress as previously highlighted by Eisenberg 20.
Yet another perspective is provided by Frenkel et
al. 22. These authors suggested that, to help cancer
patients be truly informed and autonomous, physicians
need to identify the patient’s beliefs, fears, hopes, and
expectations; learn which conventional treatments have
been tried, have failed, or have been rejected and why;
make sure the patient understands the prognostic fac-
tors associated with his or her stage of disease, plus
the potential benefits and harms of conventional medi-
cine; acknowledge the patient’s spiritual and religious
values and beliefs to understand how these affect health
care choices; and assess the level of support that the
patient has from friends, family, and community.
These frameworks approach the issue of commu-
nication with patients from slightly different angles,
yet all are important, and physicians will most likely
use elements of all approaches depending on the par-
ticular situation.
Implicitly, all models suggest that CAM use should
be inquired about from the beginning of contact with
the patient, ideally before the patient starts using CAM.
This emphasis suggests that CAM use should be made
a regular part of history-taking. Physicians therefore
need effective communication skills to fulfil a variety
of roles, including collecting medical histories, answer-
ing patients’ questions, developing interpersonal rela-
tions, and suggesting treatment 16. Although this need
seems obvious, it is yet another demand on physicians
working in often busy and stressful situations.
Lastly, it is important to consider that, although
disclosure of CAM is essential, successful communi-
cation hinges on supporting patient autonomy even when
the patient is making the decision to use a therapy of
which a physician does not approve.
2.3 Current and Future Trends in Patient–Provider
CAM Discussion
The importance of talking with patients about CAM thera-
pies is currently receiving much attention. Recently, the
National Center for Complementary and Alternative
Medicine (NCCAM) in the United States started the Time
to Talk campaign 23, urging health care providers to talk
about CAM. The NCCAM Web site also includes tips on
how to talk with patients. In addition, the British Medi-
cal Journal recently published a challenging editorial,
“Wham, bam, thank you CAM” 24, highlighting the need
to discuss CAM; however, the author’s question, “Alter-
native medicine is wildly popular ... but what are we
supposed to do about it?” raises the challenge of finding
relevant, evidence-based information.
Uncovering evidence-based information is espe-
cially difficult given the large number and heterogene-
ity of CAM interventions. As a result, only a limited
number of interventions have been adequately tested.
Limited time in which to learn about CAM and to dis-
cuss CAM-related issues in patient consultations that
are often already too short to address all patients’ con-
cerns poses yet another challenge for physicians.
Currently, no single resource contains comprehen-
sive summaries of the evidence base of all CAM treat-
ments relevant for patients diagnosed with cancer. In
addition, the available evidence changes almost daily.
However, helpful information can be found in a num-
ber of places. Table II includes a list of evidence-based
CAM resources that may help physicians when talking
to patients about CAM. Most are Web sites, because
these are much easier to access (and are updated more
regularly) than are books and articles. We recommend
that physicians track the sources they access and find
helpful, so that those sources are readily available when
needed. Information on how to evaluate the wide range
of CAM information sources on the Web is available
from NCCAM in the United States 25.
Because patients may see CAM practitioners for
cancer and cancer-related symptoms, it is also benefi-
cial to be informed about the CAM practitioners in the
local area who are seeing cancer patients. The Prince of
Wales Foundation for Integrated Health in the United
Kingdom has published several guides for patients using
CAM 26. These guides include helpful information on
finding CAM practitioners and asking the right questions
about those practitioners. An important aspect to assess
is whether a given CAM profession is regulated and
whether a specific practitioner has adequate credentials.
It will be important in the future to ensure that CAM
is a topic in medical education, because all graduating
physicians will encounter this issue in their practice.
The Canadian CAM in UME (undergraduate medical
education) Web site provides useful resources for those
involved in teaching medical students about CAM 17.
For physicians already in practice, continuing medical
education may be a solution; however, most important
is what can be learned from talking with patients: not
only what they use, but also what their questions are.
3. CONCLUSIONS
Many people have already been using CAM before a
cancer diagnosis, and they consider it to be part of their
health care. It is important to note that it is not possible
to provide evidence-based, patient-centred care with-
out engaging in a discussion of CAM, including an ex-
ploration of the patient’s beliefs. Patients may be
reluctant to discuss CAM because of a fear of rejection
or because of their beliefs about the complete safety of
CAM. It is therefore important that physicians initiate
discussion of the topic—ideally, early in the relation-
ship (for example, during initial history-taking), before
patients have made any decisions about CAM treatments.
It truly is time to talk about CAM with patients.
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TABLE II Resource books and Web sites
The Desktop Guide to Complementary and Alternative Medicine: An Evidence-based Approach
Ernst E, Pittler MH, Wider B, editors.
2nd edition, 2006
480 pages, paperback
Integrative Medicine: Principles for Practice
(Chapter 23, pp. 535–549)
Kligler B, Lee R.2004
700 pages, hardcover
Complementary and Alternative Medicine Secrets: Q&As about Integrating CAM Therapies into Clinical Practice
(Chapters 54 and 55, pp. 363–388)
Kohatsu W.
2002
456 pages, paperback
Integrative Medicine
(Section 13, pp. 809–899; evidence for all treatments is rated)
Rakel D.
2nd edition, 2007
1238 pages, hardcover
The Oxford Handbook of Complementary Medicine
Ernst E, Pittler MH, Wider B, Boddy K.
2008
512 pages, paperback
CAMline
www.camline.ca
Center for Health and Healing
(a service of Beth Israel Medical Center in New York)
www.healthandhealingny.org
National Center for Complementary and Alternative Medicine (NCCAM)
nccam.nih.gov/health
Natural Medicines Comprehensive Database
www.naturaldatabase.com
Natural Medicines Comprehensive Database—Clinical Management Series
www.naturaldatabase.com/(S(st2arzb2hbi2v355rtipno2p))/nd/ClinicalMngt.aspx?cs=&s=ND
Natural Standard Database
www.naturalstandard.com
Turning Research into Practice (TRIP)
databasewww.tripdatabase.com
The University of Texas MD Anderson Cancer CenterComplementary/Integrative Medicine Education Resources
www.mdanderson.org/departments/cimer
Memorial Sloan–Kettering Cancer Center
www.mskcc.org/mskcc/html/44.cfmVERHOEF et al.
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